Form 4: Prime Medicine Executive Ann Lee Gains 80,416 Shares as Performance Milestone Achieved

Ann Lee, Chief Technical Officer of Prime Medicine, Inc., acquired 80,416 shares of common stock due to the vesting of a stock option following the achievement of a performance milestone.

Summary

• Ann Lee, the Chief Technical Officer of Prime Medicine, Inc., has reported a change in beneficial ownership of securities.
• On May 8, 2025, Ms. Lee acquired 80,416 shares of Prime Medicine's common stock through the vesting of a stock option.
• This vesting was triggered by the achievement of a performance milestone determined by the company's board of directors.
• The stock option, initially granted on October 27, 2021, has an exercise price of $3.67.
• Following this transaction, Ms. Lee directly owns 241,248 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The vesting of shares due to a performance milestone suggests the company is progressing towards its goals. However, it's a routine filing and doesn't provide significant new information about the company's overall financial health or future prospects.

Positives

• The vesting of shares indicates that Prime Medicine achieved a performance milestone, which could be viewed positively by investors.
• The increased share ownership aligns the executive's interests with those of the shareholders.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in the biotechnology industry where stock options are frequently used to incentivize and retain key personnel. The vesting of options tied to performance milestones is a standard practice to align executive compensation with company goals.

Comparison to Industry Standards

• Stock option grants and vesting schedules are common compensation tools in the biotech industry.
• Companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics also utilize stock options and performance-based equity awards for their executives.
• The specific terms of these grants, such as vesting schedules and performance milestones, vary depending on the company's stage of development and strategic goals.

Stakeholder Impact

• The vesting of shares could have a slightly positive impact on shareholder sentiment as it indicates progress towards company goals.
• The increased share ownership aligns the executive's interests with those of the shareholders.

Key Dates

Keywords

Prime Medicine, Ann Lee, stock option, performance milestone, beneficial ownership, Form 4, PRME, vesting, shares